Figure 1

Dissolution profiles at pH 6.8 of non-film coated 40 mg oxycodone HCl tablets, obtained according to Example 1.




Figure 2

Dissolution profiles at pH 6.8 of non-film coated 40 mg oxycodone HCl tablets, obtained according to Example 2.




Figure 3

Dissolution profile at pH 6.8 of tablets conforming to Example 2, film-coated with a layer of Ethylcellulose EC30 D and subjected to a curing step




Figure 4

Comparative dissolution profiles of oxycodone matrix tablets conforming to the invention in an ethanol-free 0.1 N HCl medium and in a 0.1 N HCl medium containing 40 % ethanol




Figure 5

Dissolution profiles of oxycodone matrix tablets conforming to the invention in two dissolution media of different pH (1.2 and 6.8)




Figure 6

24-hour dissolution profiles of 40 mg oxycodone tablets conforming to the invention after a storage period in Al/Al blister pack under accelerated stability conditions of 1 month, 2 months, 3 months and 6 months.




Figure 7

24-hour dissolution profiles of 20 mg oxycodone tablets conforming to the invention after a storage period in HDPE bottles with desiccant under accelerated stability conditions of 1 month, 2 months and 3 months.




Figure 8

Plasma profiles of oxycodone after once-a-day administering of 40 mg oxycodone tablets conforming to the invention, and 40 mg oxycodone tablets of the reference product Oxycontin®




Figure 9

24-hour dissolution profile of ultra-hard non-coated tablets containing oxycodone and naloxone, at pH 6.8.




Figure 10

10-hour dissolution profiles at pH 6.8 of ultra-hard, non-coated 20 mg oxycodone tablets comprising a matrix containing mineral excipients




Figure 11

Dissolution profiles of tablets conforming to the invention(« QD ») and tablets of the reference product Oxycontin® (ref) at pH 6.8, for whole tablets, tablets cut in half, or crushed (« in pieces »)

